Healthcare
•3762 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3762)
| Company | Market Cap | Price |
|---|---|---|
|
SCPH
scPharmaceuticals Inc.
FUROSCIX is a cardiovascular drug (diuretic) approved for heart failure and CKD, representing SCPH's core product.
|
$299.33M |
$5.67
|
|
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
Lead programs are oral small-molecule therapeutics targeting NI&I indications.
|
$298.65M |
$10.30
-3.29%
|
|
KYTX
Kyverna Therapeutics, Inc.
KYTX's lead and pipeline CAR-T products (KYV-101, KYV-102, KYV-201) are autologous/allogeneic CD19 CAR-T cell therapies, a direct cell therapy product category.
|
$297.35M |
$6.42
-6.69%
|
|
MREO
Mereo BioPharma Group plc
Mereo's core focus is developing therapeutics for rare diseases, fitting the Biotech - Rare Diseases category.
|
$295.74M |
$1.79
-3.49%
|
|
DMAC
DiaMedica Therapeutics Inc.
DMAC's lead DM199 is a peptide/protein-based therapeutic (recombinant KLK1) aimed at treating AIS and PE.
|
$291.61M |
$6.75
-0.74%
|
|
CERS
Cerus Corporation
Cerus' INTERCEPT Blood System is a medical device platform; primary product is a device used in transfusion safety.
|
$290.56M |
$1.47
-3.62%
|
|
CIA
Citizens, Inc.
Accident & health (A&H) / health insurance offerings are mentioned as part of the product mix.
|
$288.96M |
$5.73
-1.04%
|
|
BWAY
BrainsWay Ltd.
Core product: BrainsWay's Deep TMS neuromodulation devices.
|
$288.87M |
$16.88
-2.88%
|
|
SPOK
Spok Holdings, Inc.
GenA alphanumeric pager represents a medical device hardware line under Medical Devices & Biometrics.
|
$286.42M |
$13.76
-1.08%
|
|
SMLR
Semler Scientific, Inc.
QuantaFlo is a diagnostic device used to measure arterial blood flow for PAD, directly constituting Diagnostic Equipment.
|
$283.36M |
$23.98
-5.63%
|
|
AVIR
Atea Pharmaceuticals, Inc.
Atea's lead program comprises antiviral small-molecule therapeutics targeting HCV.
|
$278.13M |
$3.21
-1.23%
|
|
CAPR
Capricor Therapeutics, Inc.
Capricor's lead asset deramiocel is a cell-based therapy, the core product offering of the company.
|
$277.45M |
$6.26
+3.13%
|
|
ACRS
Aclaris Therapeutics, Inc.
Company's focus is on immuno-inflammatory diseases, aligning with Immunology Therapeutics.
|
$277.20M |
$2.42
-5.27%
|
|
DBVT
DBV Technologies S.A.
Viaskin Peanut EPIT patch is a drug-delivery platform; DBV Technologies directly develops and commercializes this patch-based immunotherapy.
|
$275.03M |
$14.53
+1.96%
|
|
TKNO
Alpha Teknova, Inc.
Teknova is the exclusive US/Canada manufacturer and distributor of the PluriFreeze PF10 cryopreservation system, a medical device.
|
$271.48M |
$4.74
-6.79%
|
|
CVRX
CVRx, Inc.
CVRx's Barostim is a neuromodulation device (implantable) that modulates the autonomic nervous system via baroreflex activation for heart failure.
|
$270.11M |
$10.00
-3.47%
|
|
OMI
Owens & Minor, Inc.
OMI sells and distributes medical devices and biometric equipment for home healthcare and clinical use.
|
$266.49M |
$3.50
+1.30%
|
|
IMMP
Immutep Limited
Immutep is focused on immunology therapeutics, including LAG-3 modulation for cancer and autoimmune diseases.
|
$266.37M |
$1.83
|
|
BIOA
BioAge Labs, Inc.
BioAge's lead program BGE-102 is an oral small-molecule therapeutic, and APJ agonists are being developed for obesity, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$266.01M |
$7.51
+1.21%
|
|
VNDA
Vanda Pharmaceuticals Inc.
Fanapt and other marketed/potential small-molecule therapies (e.g., Tradipitant) are oral small molecule therapeutics.
|
$264.13M |
$4.34
-2.80%
|
|
SGHT
Sight Sciences, Inc.
Directly manufactures ophthalmic surgical devices (OMNI Surgical System, TearCare-related tools) used in eye care, i.e., ophthalmology devices.
|
$263.68M |
$4.99
-2.16%
|
|
LFCR
Lifecore Biomedical, Inc.
Lifecore is a pure-play CDMO focused on sterile injectable drug development and manufacturing.
|
$263.25M |
$6.80
-4.36%
|
|
CADL
Candel Therapeutics, Inc.
CAN-2409 and CAN-3110 are viral vector-based therapies, aligning with gene therapy.
|
$261.54M |
$5.12
-2.01%
|
|
ELDN
Eledon Pharmaceuticals, Inc.
Tegoprubart is an IgG1 monoclonal antibody therapeutic targeting CD40L.
|
$261.08M |
$4.17
-4.36%
|
|
LFMD
LifeMD, Inc.
LifeMD operates as a healthcare services provider with a multi-state medical group and in-house pharmacy; core service delivery.
|
$260.87M |
$5.45
-5.14%
|
|
VMD
Viemed Healthcare, Inc.
Viemed operates as an in-home healthcare provider delivering home health and hospice services.
|
$259.67M |
$6.58
+0.15%
|
|
SGMT
Sagimet Biosciences Inc.
Sagimet's lead and second FASN inhibitors (denifanstat, TVB-3567) are oral small-molecule therapeutics, directly aligning with this tag.
|
$259.49M |
$7.84
-2.67%
|
|
ALLO
Allogene Therapeutics, Inc.
Direct product category: off-the-shelf allogeneic CAR-T cell therapies (Allogene's core platform and pipeline).
|
$258.10M |
$1.10
-6.36%
|
|
SMTI
Sanara MedTech Inc.
bone fusion/orthopedic implants (BiFORM, ALLOCYTE Plus) and associated bone void filler (OsStic) place the company in Orthopedic Devices.
|
$257.66M |
$28.27
-2.50%
|
|
TRDA
Entrada Therapeutics, Inc.
Entrata's primary value proposition is its Drug Delivery Platform (EEV) enabling intracellular delivery of therapeutics.
|
$257.32M |
$6.62
-2.43%
|
|
INZY
Inozyme Pharma, Inc.
Inozyme focuses on ENPP1 Deficiency, a rare disease, with INZ-701 as a lead therapy, making it a dedicated rare-disease biopharma company.
|
$256.96M |
$4.00
|
|
EDIT
Editas Medicine, Inc.
Core product category: in vivo gene therapy using Editas's gene-editing platform (AsCas12a) delivered via targeted lipid nanoparticles (tLNP).
|
$256.16M |
$2.84
-7.19%
|
|
CNFN
CFN Enterprises Inc.
CNFN's Ranco segment operates as a contract manufacturer/co-packer and white-label producer for clients.
|
$255.19M |
$2.15
|
Showing page 20 of 38 (3762 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
